Thorsten Marquardt

Prof. Dr. Thorsten Marquardt

Klinik für Kinder- und Jugendmedizin – Allgemeine Pädiatrie, Universitätsklinikum Münster, Münster, Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JPJulien Park
Julien Park
MHMax Hogrebe
Max Hogrebe
MGMarianne Grüneberg
Marianne Grüneberg
IDIngrid DuChesne
Ingrid DuChesne
AHAva L. von der Heiden
Ava L. von der Heiden
TMThorsten Marquardt
Thorsten Marquardt

15 March 2003 in European Journal of Pediatrics
Verified
Journal Article
Closed access
TMThorsten Marquardt
Thorsten Marquardt
JDJ. Denecke
J. Denecke

10 January 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
Sarah GrünertSarah Grünert
Sarah Grünert
SMStephanie Müllerleile
Stephanie Müllerleile
LSLinda De Silva
Linda De Silva
MBMichael Barth
Michael Barth
MWMelanie Walter
Melanie Walter
JSJörn Oliver Sass
Jörn Oliver Sass
Background: Propionic acidemia is an inherited disorder caused by deficiency of propionyl-CoA carboxylase. Although it is one of the most frequent organic acidurias, information on the outcome of affected individuals is still limited. Study design/methods: Clinical and outcome data of 55 patients with propionic acidemia from 16 European metabolic centers were evaluated retrospectively. 35 patients were diagnosed by selective metabolic screening while 20 patients were identified by newborn screening. Endocrine parameters and bone age were evaluated. In addition, IQ testing was performed and the patients’ and their families’ quality of life was assessed. Results: The vast majority of patients (>85%) presented with metabolic decompensation in the neonatal period. Asymptomatic individuals were the exception. About three quarters of the study population was mentally retarded, median IQ was 55. Apart from neurologic symptoms, complications comprised hematologic abnormalities, cardiac diseases, feeding problems and impaired growth. Most patients considered their quality of life high. However, according to the parents’ point of view psychic problems were four times more common in propionic acidemia patients than in healthy controls. Conclusion: Our data show that the outcome of propionic acidemia is still unfavourable, in spite of improved clinical management. Many patients develop long-term complications affecting different organ systems. Impairment of neurocognitive development is of special concern. Nevertheless, self-assessment of quality of life of the patients and their parents yielded rather positive results.

1 August 2016 in Molecular Genetics and Metabolism
Verified
Journal Article
Open access
MVMarie T. Vanier
Marie T. Vanier
Paul GissenPaul Gissen
Paul Gissen
PBPeter Bauer
Peter Bauer
MCMaria J. Coll
Maria J. Coll
alberto burlinaalberto burlina
alberto burlina
SKStefan A. Kolb
Stefan A. Kolb
Niemann-Pick disease type C (NP-C) is a neurovisceral lysosomal cholesterol trafficking and lipid storage disorder caused by mutations in one of the two genes, NPC1 or NPC2. Diagnosis has often been a difficult task, due to the wide range in age of onset of NP-C and clinical presentation of the disease, combined with the complexity of the cell biology (filipin) laboratory testing, even in combination with genetic testing. This has led to substantial delays in diagnosis, largely depending on the access to specialist centres and the level of knowledge about NP-C of the physician in the area. In recent years, advances in mass spectrometry has allowed identification of several sensitive plasma biomarkers elevated in NP-C (e.g. cholestane-3β,5α,6β-triol, lysosphingomyelin isoforms and bile acid metabolites), which, together with the concomitant progress in molecular genetic technology, have greatly impacted the strategy of laboratory testing. Specificity of the biomarkers is currently under investigation and other pathologies are being found to also result in elevations. Molecular genetic testing also has its limitations, notably with unidentified mutations and the classification of new variants. This review is intended to increase awareness on the currently available approaches to laboratory diagnosis of NP-C, to provide an up to date, comprehensive and critical evaluation of the various techniques (cell biology, biochemical biomarkers and molecular genetics), and to briefly discuss ongoing/future developments. The use of current tests in proper combination enables a rapid and correct diagnosis in a large majority of cases. However, even with recent progress, definitive diagnosis remains challenging in some patients, for whom combined genetic/biochemical/cytochemical markers do not provide a clear answer. Expertise and reference laboratories thus remain essential, and further work is still required to fulfill unmet needs.

1 February 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
TBTatiana Bremova-Ertl
Tatiana Bremova-Ertl
URUma Ramaswami
Uma Ramaswami
MBMarion Brands
Marion Brands
TFTomas Foltan
Tomas Foltan
MGMatthias Gautschi
Matthias Gautschi
Kyriakos MartakisKyriakos Martakis
Kyriakos Martakis
Niemann-Pick disease type C is a rare lysosomal storage disorder. We evaluated the safety and efficacy of N-acetyl-l-leucine (NALL), an agent that potentially ameliorates lysosomal and metabolic dysfunction, for the treatment of Niemann-Pick disease type C. In this double-blind, placebo-controlled, crossover trial, we randomly assigned patients 4 years of age or older with genetically confirmed Niemann-Pick disease type C in a 1:1 ratio to receive NALL for 12 weeks, followed by placebo for 12 weeks, or to receive placebo for 12 weeks, followed by NALL for 12 weeks. NALL or matching placebo was administered orally two to three times per day, with patients 4 to 12 years of age receiving weight-based doses (2 to 4 g per day) and those 13 years of age or older receiving a dose of 4 g per day. The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status). Secondary end points included scores on the Clinical Global Impression of Improvement, the Spinocerebellar Ataxia Functional Index, and the Modified Disability Rating Scale. Crossover data from the two 12-week periods in each group were included in the comparisons of NALL with placebo. A total of 60 patients 5 to 67 years of age were enrolled. The mean baseline SARA total scores used in the primary analysis were 15.88 before receipt of the first dose of NALL (60 patients) and 15.68 before receipt of the first dose of placebo (59 patients; 1 patient never received placebo). The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001). The results for the secondary end points were generally supportive of the findings in the primary analysis, but these were not adjusted for multiple comparisons. The incidence of adverse events was similar with NALL and placebo, and no treatment-related serious adverse events occurred. Among patients with Niemann-Pick disease type C, treatment with NALL for 12 weeks led to better neurologic status than placebo. A longer period is needed to determine the long-term effects of this agent in patients with Niemann-Pick disease type C. (Funded by IntraBio; ClinicalTrials.gov number, NCT05163288; EudraCT number, 2021-005356-10.).

1 March 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CKChristian Kranz
Christian Kranz
CJChristoph Jungeblut
Christoph Jungeblut
JDJonas Denecke
Jonas Denecke
AEAnne Erlekotte
Anne Erlekotte
CSChristina Sohlbach
Christina Sohlbach
TMThorsten Marquardt
Thorsten Marquardt